Living with ALK+

YOU & ALK+ LUNG CANCER

With Passion for Our Patients

We understand that being diagnosed with lung cancer is the beginning of a difficult journey. But you are not alone on this journey, in addition to your friends and family, your healthcare team is there for you, guiding the way through treatment and therapy.

We, at Xcovery made it our aim to improve the lives of cancer patients like you, by discovering and developing innovative medicines to fight the disease. Our passion is to bring back humanity to cancer treatment and with this we committed to bettering lives by providing improved therapies.

YOU & ALK+ LUNG CANCER

With Passion for Our Patients

We understand that being diagnosed with lung cancer is the beginning of difficult journey. But you are not alone on this journey, in addition to your friends and family, your healthcare team is there for you, guiding the way through treatment and therapy.

We, at Xcovery made it our aim to improve the lives of cancer patients like you, by discovering and developing innovative medicines to fight the disease. Our passion is to bring back humanity to cancer treatment and with this we committed to bettering lives by providing improved therapies.

WHAT IS ALK+ LUNG CANCER?

There are many different types of lung cancer. The two major types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common form, making up 85-90% of all cases. There are also different forms of NSCLC that can be differentiated by the type of cells they contain and their genetic make-up. Cancer cells harbor diverse genetic alterations, which help them grow. It is these alterations that also make the tumors vulnerable to specific, so-called “targeted” medicines.

Contrary to common belief, lung cancer is not always associated with smoking; non-smokers can also be affected. This is especially true for ALK+ (Anaplastic Lymphoma Kinase positive) lung cancer, as many of the patients have never or only lightly smoked. In this form of the disease, the ALK fusion gene, a component in the lung cells, is abnormally activated. This can cause the cells to grow and develop without control, which can lead to cancer. The reason for this activation is an alteration of the ALK gene. In ALK+ lung cancer, the ALK gene is fused to the EML4 gene, which results in the production of a new protein called EML4-ALK. This fusion protein functions in the same way as the ALK protein, but it is active when it shouldn’t be.

cancer cure
innovative medicines

WHAT IS ENSARTINIB?

ALK is not active in most adult tissues and organs; therefore cells with active ALK can be identified as cancer cells and be differentiated from healthy cells. This makes ALK an attractive target. Ensartinib is a targeted drug that specifically blocks ALK and, with this, may prevent the cancer cells from growing, whereas healthy cells remain largely unaffected. Due to this targeted approach, the goal of ensartinib is to provide a treatment with lower toxicity and fewer side effects than other treatments. Ensartinib is given orally; this is beneficial for the quality of life of patients, as the drug can be taken at home, unlike therapies that are administered by injections or infusions. We are currently conducting clinical studies to evaluate the safety of ensartinib and to see how ALK+ lung tumors respond to this medication. Based on previous research, we think that ensartinib has the potential to block ALK more strongly than other available treatments.

Interested in participating in a clinical study?
LEARN MORE

WHAT IS ALK+ LUNG CANCER

Lung cancer is not one single disease, but in fact there are many different types. The two major types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common form, making up 85-90% of all cases. There are also different forms of NSCLC that can be differentiated by the type of cells they contain and their genetic make-up. Cancer cells harbor diverse genetic alterations, which help them grow.

It is these alterations that also make the tumors vulnerable to specific, so-called “targeted” medicines. Contrary to common belief, lung cancer is not always associated with smoking; non-smokers can also be affected. This is especially true for ALK+ (Anaplastic Lymphoma Kinase positive) lung cancer, as many of the patients have never or only lightly smoked. In this form of the disease, the ALK fusion gene, a component in the lung cells, is abnormally activated. This can cause the cells to grow and develop without control, which can lead to cancer.

The reason for this activation is an alteration of the ALK gene. In ALK+ lung cancer, the ALK gene is fused to the EML4 gene, which results in the production of a new protein called EML4-ALK. This fusion protein functions in the same way as the ALK protein, but it is active when it shouldn’t be.

WHAT IS ENSARTININB

ALK is not active in most adult tissues and organs; therefore cells with active ALK can be identified as cancer cells and be differentiated from healthy cells. This makes ALK an attractive target. Ensartinib is a targeted drug that specifically blocks ALK and, with this, may prevent the cancer cells from growing, whereas healthy cells remain largely unaffected. Due to this targeted approach, the goal of ensartinib is to provide a treatment with lower toxicity and fewer side effects than other treatments.

Ensartinib is given orally; this is beneficial for the quality of life of patients, as the drug can be taken at home, unlike therapies that are administered by injections or infusions. We are currently conducting clinical studies to evaluate the safety of ensartinib and to see how ALK+ lung tumors respond to this medication. Based on previous research, we think that ensartinib has the potential to block ALK more strongly than other available treatments.

Intersted in participating in a clinical study?

LEARN MORE

EXPANDED ACCESS POLICY

Xcovery is currently supporting expanded access, including for emergency use, for individual patients without other appropriate treatment options.

Please contact trials@xcovery.com for additional information.

YOUR RESOURCES

National Cancer Institute

The nation’s leading agency for cancer research, providing information for patients and healthcare providers.

Bonnie J. Addario Lung Cancer Foundation

This foundation is devoted exclusively to eradicating lung cancer through a variety of outlets.

Free to Breathe

Free to Breathe is an organization whose goal is to double the lung cancer survival rate by 2022. The organization focuses on funding research, increasing the number of lung cancer patients participating in clinical studies, as well as building the lung cancer community.

Inspire

Inspire allows individuals to start and participate in discussions related to various medical topics. Inspire has various communities for those affected by lung cancer to join and interact with fellow patients, caregivers, and survivors.

Lung Cancer Alliance

This organization’s aim is to triple the number of lung cancer survivors over the next decade through research, access to quality care, and framing the conversation. Moreover, this organization provides education and treatment options to lung cancer patients.

Lung Cancer Foundation of America

Lung Cancer Foundation of America raises funds to increase support of innovative and groundbreaking research efforts in lung cancer.

LungCancer.org

LungCancer.org is a source of education materials on lung cancer, as well as support opportunities for patients.

Lungevity Foundation

Lungevity is a lung cancer-focused nonprofit organization that aims to change outcomes for people with lung cancer through research, education, and support.

Lung Cancer Research Foundation

The foundation raises money to support research and individuals whose lives have been changed by lung cancer.

ClinicalTrials.gov

ClinicalTrials.gov is a registry and database of clinical studies of human participants conducted around the world.